Coronary artery disease: Difference between revisions
From IDWiki
No edit summary |
(→) |
||
Line 1: | Line 1: | ||
== |
==Background== |
||
=== |
===Risk Factors=== |
||
* |
*Modifiable: tobacco use, [[dyslipidemia]], [[diabetes mellitus]], [[hypertension]], [[chronic kidney disease]], physical inactivity, diet, [[obesity]], [[metabolic syndrome]], [[depression]] |
||
* |
*Non-modifiable: age, sex, family history of premature cardiovascular disease, ethnic origin |
||
==Investigations== |
==Investigations== |
||
Line 27: | Line 27: | ||
*Medical management |
*Medical management |
||
**Secondary prevention |
|||
**Prevention |
|||
***Antiplatelet |
***Antiplatelet |
||
****ASA, with a PPI if history of GI bleeding |
****ASA, with a PPI if history of GI bleeding |
||
****If ASA allergy |
****If ASA allergy, use [[clopidogrel]] |
||
***BP control |
***BP control, preferentially with ACE inhibitor or ARB |
||
***If heart failure, ACE inhibitor or ARB |
|||
***[[Statin]] |
***[[Statin]] regardless of cholesterol |
||
**Anti-anginal medications |
**Anti-anginal medications |
||
***[[Beta blockers]] |
***[[Beta blockers]], which is the only one with possible mortality benefit |
||
***[[Calcium channel blockers]] |
***[[Calcium channel blockers]] |
||
***[[Nitrates]] |
***[[Nitrates]] |
||
**[[ACEi]] if heart failure |
|||
*Cardiac rehab |
*Cardiac rehab |
||
*Procedures |
*Procedures |
||
Line 53: | Line 53: | ||
*Exercise and education |
*Exercise and education |
||
== |
==Further Reading== |
||
* |
*Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease. ''Can J Cardiol''. 2014;30(8):837-849. doi: https://doi.org/10.1016/j.cjca.2014.05.013 |
||
[[Category:Cardiology]] |
[[Category:Cardiology]] |
Latest revision as of 16:23, 23 February 2021
Background
Risk Factors
- Modifiable: tobacco use, dyslipidemia, diabetes mellitus, hypertension, chronic kidney disease, physical inactivity, diet, obesity, metabolic syndrome, depression
- Non-modifiable: age, sex, family history of premature cardiovascular disease, ethnic origin
Investigations
- Fasting lipids and HbA1c, to assess cardiovascular risk and guide risk reduction treatment
- Stress test: exercise or persantine/dobutamine; ECG or echo or nuclear (mibi); see below
- Nuclear perfusion scan (mibi) or stress echo, for risk stratification and identification of reversible perfusion defects
- Angiography, for direct coronary visualization and diagnosis, and possible angioplasty
- Done for high risk features on stress testing
Stress Test
graph LR; LBBB_etc[LBBB or V-paced] --yes--> mibi[persantine mibi] LBBB_etc --no--> exercise[can exercise?] exercise --yes--> normal_ecg[ECG normal] exercise --no--> either[persantine mibi or dobutamine echo] normal_ecg --yes--> exercise_ecg[exercise ECG] normal_ecg --no--> exercise_either[exercise mibi or echo]
Management
- Medical management
- Secondary prevention
- Antiplatelet
- ASA, with a PPI if history of GI bleeding
- If ASA allergy, use clopidogrel
- BP control, preferentially with ACE inhibitor or ARB
- If heart failure, ACE inhibitor or ARB
- Statin regardless of cholesterol
- Antiplatelet
- Anti-anginal medications
- Beta blockers, which is the only one with possible mortality benefit
- Calcium channel blockers
- Nitrates
- Secondary prevention
- Cardiac rehab
- Procedures
- Angioplasty (percutaneous intervention [PCI])
- Requires dual antiplatelet therapy (DAPT) for up to 1 year (for drug-eluting stents)
- Coronary artery bypass surgery (CABG)
- Better for multivessel disease, diabetics
- Angioplasty (percutaneous intervention [PCI])
ABCDE
- Antiplatelets and ACEi/ARB
- Beta blockers and BP
- Cholesterol, cigarettes, and cease hormone-replacement therapy
- Diet and diabetes
- Exercise and education
Further Reading
- Canadian Cardiovascular Society Guidelines for the Diagnosis and Management of Stable Ischemic Heart Disease. Can J Cardiol. 2014;30(8):837-849. doi: https://doi.org/10.1016/j.cjca.2014.05.013